185 related articles for article (PubMed ID: 8879230)
61. Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene.
Krämer S; Schimpl A; Hünig T
J Exp Med; 1995 Dec; 182(6):1769-76. PubMed ID: 7500021
[TBL] [Abstract][Full Text] [Related]
62. Imaging features of multicentric Castleman's disease in HIV infection.
Hillier JC; Shaw P; Miller RF; Cartledge JD; Nelson M; Bower M; Francis N; Padley SP
Clin Radiol; 2004 Jul; 59(7):596-601. PubMed ID: 15208065
[TBL] [Abstract][Full Text] [Related]
63. Fibrillary glomerulonephritis in Castleman's disease.
Miadonna A; Salmaso C; Palazzi P; Elli A; Braidotti P; Lambertenghi Deliliers G
Leuk Lymphoma; 1998 Jan; 28(3-4):429-35. PubMed ID: 9517516
[TBL] [Abstract][Full Text] [Related]
64. Fulminant multicentric Castleman's disease in a patient with well-controlled human immunodeficiency virus infection-lessons from the patient.
Chen TC; Tseng HH; Wong LC
J Formos Med Assoc; 2018 Mar; 117(3):244-246. PubMed ID: 28666716
[No Abstract] [Full Text] [Related]
65. Castleman's disease.
Shahidi H; Myers JL; Kvale PA
Mayo Clin Proc; 1995 Oct; 70(10):969-77. PubMed ID: 7564550
[TBL] [Abstract][Full Text] [Related]
66. [Diagnosis and treatment of 41 cases of head and neck Castleman's disease].
Xue JF; Hao Q; Zhang YM; Cao PD; Song SP; Hu RF; Jin S
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Aug; 53(8):610-614. PubMed ID: 30122000
[No Abstract] [Full Text] [Related]
67. Functional analysis of IL-6 and IL-6DBP/C/EBP beta by gene targeting.
Fattori E; Sellitto C; Cappelletti M; Lazzaro D; Bellavia D; Screpanti I; Gulino A; Costantini F; Poli V
Ann N Y Acad Sci; 1995 Jul; 762():262-73. PubMed ID: 7545366
[No Abstract] [Full Text] [Related]
68. IL-6 expression helps distinguish Castleman's disease from IgG4-related disease in the lung.
Kinugawa Y; Uehara T; Iwaya M; Asaka S; Kobayashi S; Nakajima T; Komatsu M; Yasuo M; Yamamoto H; Ota H
BMC Pulm Med; 2021 Jul; 21(1):219. PubMed ID: 34246246
[TBL] [Abstract][Full Text] [Related]
69. Analysis of Clinical Characteristics, Pathological Changes and Changes of Interleukin-6 (IL-6) and C-Reactive Protein (CRP) in Children with Castleman's Disease.
Hu C; Zou Y; Pan J; Yang J; Yang T; Tan T; Li J
Med Sci Monit; 2020 Aug; 26():e924783. PubMed ID: 32873770
[TBL] [Abstract][Full Text] [Related]
70. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
71. Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease.
Terasaki Y; Ikushima S; Matsui S; Hebisawa A; Ichimura Y; Izumi S; Ujita M; Arita M; Tomii K; Komase Y; Owan I; Kawamura T; Matsuzawa Y; Murakami M; Ishimoto H; Kimura H; Bando M; Nishimoto N; Kawabata Y; Fukuda Y; Ogura T;
Histopathology; 2017 Jun; 70(7):1114-1124. PubMed ID: 28207938
[TBL] [Abstract][Full Text] [Related]
72. [Multicentric Castleman's disease (MCD): recent knowledge of its pathogenesis].
Higashibara M; Horie R; Yoneyama A; Mori S
Rinsho Ketsueki; 1992 Nov; 33(11):1649-60. PubMed ID: 1469779
[No Abstract] [Full Text] [Related]
73. High level activity of the mouse CCAAT/enhancer binding protein (C/EBP alpha) gene promoter involves autoregulation and several ubiquitous transcription factors.
Legraverend C; Antonson P; Flodby P; Xanthopoulos KG
Nucleic Acids Res; 1993 Apr; 21(8):1735-42. PubMed ID: 8493090
[TBL] [Abstract][Full Text] [Related]
74. Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report.
Al Otaibi T; Al Sagheir A; Ludwin D; Meyer R
Transplant Proc; 2007 May; 39(4):1276-7. PubMed ID: 17524952
[TBL] [Abstract][Full Text] [Related]
75. Hepatic lesions of vascular origin in multicentric Castleman's disease, plasma cell type: report of one case with peliosis hepatis and another with perisinusoidal fibrosis and nodular regenerative hyperplasia.
Molina T; Delmer A; Le Tourneau A; Texier P; Degott C; Audoin J; Zittoun R; Diebold J
Pathol Res Pract; 1995 Nov; 191(11):1159-64. PubMed ID: 8822119
[TBL] [Abstract][Full Text] [Related]
76. Hyaline-vascular type Castleman's disease with concomitant malignant B-cell lymphoma.
Buijs L; Wijermans PW; van Groningen K; Gerrits WB; Kluin P; Haak HL
Acta Haematol; 1992; 87(3):160-2. PubMed ID: 1379404
[TBL] [Abstract][Full Text] [Related]
77. Castleman's disease of the spleen.
Mantas D; Damaskos C; Dailiani P; Samarkos M; Korkolopoulou P
Acta Chir Belg; 2017 Jun; 117(3):203-208. PubMed ID: 27771992
[TBL] [Abstract][Full Text] [Related]
78. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
Ohsugi Y; Tsuchimoto N
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
[No Abstract] [Full Text] [Related]
79. Activation of the Ig germ-line gamma 1 promoter. Involvement of C/enhancer-binding protein transcription factors and their possible interaction with an NF-IL-4 site.
Lundgren M; Larsson C; Femino A; Xu M; Stavnezer J; Severinson E
J Immunol; 1994 Oct; 153(7):2983-95. PubMed ID: 8089482
[TBL] [Abstract][Full Text] [Related]
80. [Castleman's Disease - A Case Series of a Rare Lymphoproliferative Disease].
Riepl R; Hoffmann TK; Greve J
Laryngorhinootologie; 2017 Aug; 96(8):522-527. PubMed ID: 28486739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
